Analysis of the Effect of Dopamine Transporter Scan on the Diagnosis and Management in a Tertiary Neurology Center

Abstract

Background and Purpose:

The dopamine transporter scan or DaT scan is abnormal in presynaptic parkinsonism but normal in nondegenerative or postsynaptic parkinsonism. In this study, we tried to ascertain the impact of DaT scan on the diagnosis and clinical management and if the semiquantitative analysis of the DaT scans has any correlation with the clinical symptoms.

Methods:

The electronic and nonelectronic records of patients of Plymouth Hospital NHS Trust, United Kingdom, from 2011 to 2015 were studied to find the indication, outcome, and the impact of the scan on the management of patients. The DaT scan results were assessed visually and semiquantitatively by the Department of Nuclear Medicine. The available data were statistically analyzed with the help of Microsoft XL2010 and GraphPad software.

Results:

A total of 258 people had DaT scan. The scan results suggested an alternate diagnosis in 50.5% of clinically diagnosed patients with Parkinson disease. Similarly, DaT scan changed the diagnosis of 40% of patients with clinical diagnosis of vascular parkinsonism, 25% of clinically diagnosed drug-induced parkinsonism, and 54% of patients with possible Lewy body dementia. Visual assessment of the DaT scan revealed that more than 60% had grade 2 abnormalities. The distribution volume ratio, a semiquantitative tool for tracer uptake, was significantly less in the patients with akinetic-rigid subtype of Parkinson disease in comparison to a tremor predominant subtype.

Conclusions:

Dopamine transporter scan had a significant impact in diagnosis and management.

Keywords

dopamine SPECT transporter presynaptic degeneration parkinsonism

Get full access to this article

View all access options for this article.

References

Djang

Janssen

Bohnen

, et al. SNM Practice guideline for dopamine transporter imaging with 123I-Ioflupane SPECT 1.0. J Nucl Med. 2012;53(1):154–163.

Darcourt

Booij

Tatsch

, et al. EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37(2):443–450.

FDA prescribing information for DaTscan. 2011. http://www.accessdata.fda.gov/drugsatfda.docs/nda/2011/022454sOrig1s000Lbl.pdf. Accessed February 02, 2018.

Bajaj

Hauser

Grachev

. Clinical utility of dopamine transporter single photon emission (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2013;84(11):1288–1295.

Goetz

Poewe

Rascol

, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. The movement disorder society task force on rating scales for Parkinson’s disease. Mov Disord. 2004;19(9):1020–1028.

Lange

Seese

Schwarzenbock

, et al. CT-Based attenuation correction in I-123-ioflupane SPECT. PLoS One. 2014;9:e108328. doi:10.1371/ journal. pone.0108328. eCollection 2014.

Parkinson’s Disease. National clinical guideline for diagnosis and management in primary and secondary care. NICE full guideline. Royal College of Physicians. London. United Kingdom: Parkinson’s Disease; 2006.

Oravivattanakul

Benchaya

, et al. Dopamine transporter (DaT) scan utilization in a movement disorder center. Mov Disord Clin Prac. 2016;3(1):31–35.

Kupsch

Bajaj

Weiland

, et al. Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study. J Neurol Neurosurg Psychiatry. 2012;83(6):620–628.

10.

Mirpour

Turkbey

Marashdeh

El Khouli

Subramaniam

. Impact of DaT-SPECT on management of patients suspected of parkinsonism. Clin Nucl Med. 2018;43(10):710–714.

11.

Sadasivan

Friedman

. Experience with DaTscan at a tertiary referral center. Parkinsonism Relat Disord. 2015;21(1):42–45.

12.

Gayed

Joseph

Fanous

, et al. The impact of DaTscan in the diagnosis of Parkinson disease. Clin Nucl Med. 2015;40(5):390–393.

13.

Brigo

Turri

Tinazzi

. 123I-FP-CIT SPECT in the differential diagnosis between dementia with Lewy bodies and other dementias. J Neurol Sci. 2015;359(1-2):161–171.

14.

Van der Zande

Booij

Scheltens

Raijmakers

Lemstra AW

. [(123)]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies. Eur J Nucl Med Mol Imaging. 2016;43(6):1060–1066.

15.

McCleery

Morgan

Bradley

Noel-Storr

Ansorge

Hyde

. Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies. Cochrane Database Syst Rev. 2015;1:CD010633. doi:10.1002/14651858.CD010633.

16.

Bhattacharjee

Chalissery

Barry

O’Sullivan

O’Connell

Lynch

. Referral practice, reporting standards, and the impact of dopamine transporter scans done in a tertiary hospital. Neurol India. 2017;65(6):1264–1270.

17.

Bega

Gonzalez-Latapi

Zadikoff

Spies

Simuni

. Is there a role for DAT-SPECT imaging in a specialty movement disorders practice? Neurodegener Dis. 2015;15(2):81–86.

18.

Van Dyck

Seibyl

Malison

, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CIT SPECT. J Nucl Med. 1995;36(7):1175–1181.

19.

Acton

Newberg

Ploessl

Mozley

. Comparison of region-of-interest analysis and human observers in the diagnosis of Parkinson’s disease using [99mTc] Trodat-1 and SPECT. Phys Med Biol. 2006;51(3):575–585.

20.

Söderlund

Dickson

Prvulovich

, et al. Value of semiquantitative analysis for clinical reporting of 123I-2-β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane SPECT studies. J Nucl Med. 2013;54(5):714–722.

21.

Albert

Unterrainer

Diemling

, et al. Implementation of the European multicentre database of healthy controls for [(123) I] FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. Eur J Nucl Med Mol Imaging. 2016;43(7):1315–1322.

22.

Rossi

Frosini

Volterrani

, et al. Differences in nigro-striatal impairment in clinical variants of early Parkinson’s disease: evidence from a FP-CIT SPECT study. Eur J Neurol. 2010;17(4):626–630.

23.

Nissen

Malek

Grosset

, et al. Baseline [123I] FP-CIT SPECT (DaTSCAN) severity correlates with medication use at 3 years in Parkinson’s disease. Acta Neurol Scand. 2014;129(3):204–208.

24.

Apostolova

Taleb

Lipp

, et al. Utility of follow-up dopamine transporter SPECT with 123I-FP-CIT in the diagnostic workup of patients with clinically uncertain Parkinsonian syndrome. Clin Nucl Med. 2017;42(8):589–594.

25.

Tolosa

Borght

Moreno

. DaTSCAN clinically uncertain parkinsonian syndromes study group. Accuracy of DaT scan (123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study. Mov Disord. 2007;22:2346–2351.

26.

Yamamoto

Arimura

Nakanishi

, et al. Age-related effects and gender differences in Japanese healthy controls for [123I] FP-CIT SPECT. Ann Nucl Med. 2017;31(5):407–412.